Chenevix-Trench G - Search Results

1

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.

Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ; AOCS Study Group; deFazio A, Chenevix-Trench G, Bowtell DD. Anglesio MS, et al. Mol Cancer Res. 2008 Nov;6(11):1678-90. doi: 10.1158/1541-7786.MCR-08-0193. Mol Cancer Res. 2008. PMID: 19010816 Free PMC article.

2

Cleft lip with or without cleft palate: associations with transforming growth factor alpha and retinoic acid receptor loci.

Chenevix-Trench G, Jones K, Green AC, Duffy DL, Martin NG. Chenevix-Trench G, et al. Am J Hum Genet. 1992 Dec;51(6):1377-85. Am J Hum Genet. 1992. PMID: 1361101 Free PMC article.

3

Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.

Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BA, Gayther SA. Foster KA, et al. Cancer Res. 1996 Aug 15;56(16):3622-5. Cancer Res. 1996. PMID: 8705994

4

Fertility and incidence of KRAS2 mutations in borderline ovarian adenocarcinomas.

Chenevix-Trench G, Coombs T, Kerr J, Purdie D, Green A, Cummings MC. Chenevix-Trench G, et al. J Natl Cancer Inst. 1997 Jun 18;89(12):890-1. doi: 10.1093/jnci/89.12.890. J Natl Cancer Inst. 1997. PMID: 9196259 No abstract available.

5

No evidence for the H133Y mutation in SONIC HEDGEHOG in a collection of common tumour types.

Wicking C, Evans T, Henk B, Hayward N, Simms LA, Chenevix-Trench G, Pietsch T, Wainwright B. Wicking C, et al. Oncogene. 1998 Feb 26;16(8):1091-3. doi: 10.1038/sj.onc.1201644. Oncogene. 1998. PMID: 9519883

6

Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer.

Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, Chenevix-Trench G. Webb PM, et al. J Natl Cancer Inst. 1998 Nov 18;90(22):1729-34. doi: 10.1093/jnci/90.22.1729. J Natl Cancer Inst. 1998. PMID: 9827528

7

CYP17 promotor polymorphism and ovarian cancer risk.

Spurdle AB, Chen X, Abbazadegan M, Martin N, Khoo SK, Hurst T, Ward B, Webb PM, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 May 1;86(3):436-9. doi: 10.1002/(sici)1097-0215(20000501)86:3<436::aid-ijc21>3.0.co;2-a. Int J Cancer. 2000. PMID: 10760835

8

Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer.

Spurdle AB, Webb PM, Chen X, Martin NG, Giles GG, Hopper JL, Chenevix-Trench G. Spurdle AB, et al. Int J Cancer. 2000 Sep 1;87(5):637-43. Int J Cancer. 2000. PMID: 10925355

9

Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication.

Boonchai W, Green A, Ng J, Dicker A, Chenevix-Trench G. Boonchai W, et al. J Am Acad Dermatol. 2000 Oct;43(4):664-9. doi: 10.1067/mjd.2000.107939. J Am Acad Dermatol. 2000. PMID: 11004623

10

Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype.

Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Spurdle AB, et al. Carcinogenesis. 2001 Jan;22(1):67-72. doi: 10.1093/carcin/22.1.67. Carcinogenesis. 2001. PMID: 11159743

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

579 results

Search Page

Filters